These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 31669768)
1. New insights into managing symptoms during statin therapy. Robinson JG Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768 [TBL] [Abstract][Full Text] [Related]
2. Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects. Peto R; Collins R Circulation; 2018 Oct; 138(15):1499-1501. PubMed ID: 30354509 [No Abstract] [Full Text] [Related]
3. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M; J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434 [TBL] [Abstract][Full Text] [Related]
4. The nocebo effect in the context of statin intolerance. Tobert JA; Newman CB J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103 [TBL] [Abstract][Full Text] [Related]
5. Muscle and statins: from toxicity to the nocebo effect. Pedro-Botet J; Climent E; Benaiges D Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941 [TBL] [Abstract][Full Text] [Related]
7. Statin Intolerance. Brown AS; Watson KE Rev Cardiovasc Med; 2018; 19(S1):S9-S19. PubMed ID: 30207553 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. Navar AM; Peterson ED; Li S; Robinson JG; Roger VL; Goldberg AC; Virani S; Wilson PWF; Nanna MG; Lee LV; Elassal J; Wang TY Circ Cardiovasc Qual Outcomes; 2018 Mar; 11(3):e004249. PubMed ID: 29545393 [No Abstract] [Full Text] [Related]
9. Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. Katsiki N; Athyros VG; Karagiannis A Curr Vasc Pharmacol; 2016; 14(6):523-533. PubMed ID: 26916398 [TBL] [Abstract][Full Text] [Related]
10. Dyslipidaemia: Statin-associated muscle symptoms - really all in the mind? Stoekenbroek RM; Kastelein JJP Nat Rev Cardiol; 2017 Aug; 14(8):445-446. PubMed ID: 28631752 [No Abstract] [Full Text] [Related]
11. SAMSON and the Nocebo Effect: Management of Statin Intolerance. Krishnamurthy A; Bradley C; Ascunce R; Kim SM Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168 [TBL] [Abstract][Full Text] [Related]
12. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cho L; Dent R; Stroes ESG; Stein EA; Sullivan D; Ruzza A; Flower A; Somaratne R; Rosenson RS Cardiovasc Drugs Ther; 2018 Aug; 32(4):365-372. PubMed ID: 30073585 [TBL] [Abstract][Full Text] [Related]
17. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Nanna MG; Navar AM; Wang TY; Mi X; Virani SS; Louie MJ; Lee LV; Goldberg AC; Roger VL; Robinson J; Peterson ED J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29739801 [TBL] [Abstract][Full Text] [Related]
18. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). Penson PE; Bruckert E; Marais D; Reiner Ž; Pirro M; Sahebkar A; Bajraktari G; Mirrakhimov E; Rizzo M; Mikhailidis DP; Sachinidis A; Gaita D; Latkovskis G; Mazidi M; Toth PP; Pella D; Alnouri F; Postadzhiyan A; Yeh HI; Mancini GBJ; von Haehling S; Banach M; J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1596-1622. PubMed ID: 35969116 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of statin therapy. Adhyaru BB; Jacobson TA Nat Rev Cardiol; 2018 Dec; 15(12):757-769. PubMed ID: 30375494 [TBL] [Abstract][Full Text] [Related]